All Press Releases
Pila Pharma AB is granted Orphan Drug Designation status in the USA
Malmö 15 July 2022 Pila Pharma AB (publ) announces that the US Food and Drug Administration, FDA, has granted Orphan Drug Designation (ODD) of the development candidate XEN-D0501 for treatment of erythromelalgia, a rare disease that causes episodes of burning pain and redness due to neurogenic inflammation. Pila Pharma's candidate molecule XEN-D0501 is otherwise under development for the treatment of…
VD Dorte X. Gram ökar sitt innehav i Pila Pharma AB
Malmö, 1 juli, 2022 Pila Pharma AB (publ) meddelar att VD Dorte X. Gram under torsdagen den 30 juni köpt 12 700 aktier i bolaget. Aktierna köptes till en snittkurs om 3,93 SEK. Affären har skett genom bolaget Gram Equity Invest som hon äger tillsammans med sin son Gustav Hanghøj Gram. Dorte X. Gram är sedan tidigare huvudägare i Pila…
CEO Dorte X. Gram increases holding in Pila Pharma AB
Malmö, July 1, 2022 Pila Pharma AB (publ) announces that CEO Dorte X. Gram on Thursday, June 30, bought 12,700 shares in the company. The shares were purchased at an average price of SEK 3.93. The transaction took place through the company Gram Equity Invest, which she owns together with her son Gustav Hanghøj Gram. Dorte X. Gram is the…